Zofran is a drug that was created by GlaxoSmithKline an antiemetic drug for nausea and vomiting (NVM) prevention. Zofran is a 5 HT3 receptor antagonist, which means it works by blocking serotonin receptors in the central nervous system as well as the GI tract. Most antiemetic drugs can be used by post-operative patients suffering from NVM, Zofran does the same as well as preventing NVM in cancer patients undergoing chemotherapy and radiation therapy.
Zofran was further marketed by GSK as a ‘safe’ anti-nausea medication for pregnant suffering from unbearable morning sickness. However, there was very little testing to prove this to be a true statement. In fact, GSK was made aware of 2 cases of birth defects in 1990, when expectant mothers took Zofran in the first 12 weeks of pregnancy. But still, tests were neglected to guarantee safety of all pregnant women who followed suit taking this drug. It is reported that by 2000 GSK had knowledge of 32 instances of birth abnormalities that were caused by their drug, in all cases the drug was taken in the early stages of pregnancy and the pregnancy resulted in a baby with a deformity.
Despite GSK’s lack of warning and testing of the effects of Zofran on pregnant women, there have been various international studies carried out that reveal that Zofran does indeed cause certain types of birth irregularities like cleft palate and congenital heart defects. To learn more about these studies go here.
Kentucky: Birth Abnormalities Data
Nearly 3,000 babies are reportedly born with one or more birth defects each year in Kentucky. In all of America it is estimated that one in 33 babies is born with a birth abnormality. Following Zofran’s entry into the US market in 1991, it became the preferred drug for relieving severe nausea and vomiting in pregnant women. The drug is believed to have had nearly 99% market share by 2005. As of 2014 Kentucky’s residents totaled 4,413,457.
Using this information, as well as the average prospects of a baby being born with a birth abnormality as specified in various epidemiological studies undertaken, we approximate that 2,570 infant births in Kentucky were affected by Zofran being ingested in the fetal development stages, therefore leading to a birth defect. The total number of residents in Kentucky’s five largest cities are:
- Louisville- 609,893 population
- Lexington- 308,428 population
- Bowling Green- 61,488 population
- Owensboro- 58,416 population
- Covington- 40,956 population
Possible Cases Of Orofacial Cleft & Hole In The Heart Abnormalities In Kentucky
Employing Kentucky’s population of 4,413,457, we have computed that there were, 415 infant birth abnormalities in the form of orofacial cleft, and 2,155 births with a hole in the heart defect. we further calculated the possible cases that exist in Kentucky’s five most inhabited cities:
- Louisville- 340 infant birth abnormalities with close to 60 orofacial cleft, and 280 hole in the heart defects
- Lexington- 195 infant birth abnormalities with close to 29 orofacial cleft, and 166 hole in the heart defects
- Bowling Green- 80 infant birth abnormalities with close to 5 orofacial cleft, and 75 hole in the heart defects
- Owensboro- 77 infant birth abnormalities with close to 5 orofacial cleft, and 72 hole in the heart defects
- Covington- 70 infant birth abnormalities with close to 5 orofacial cleft, and 65 hole in the heart defects
Cited Zofran Related Birth Defects
Recent cases that have been brought to court cite that Zofran was the main agent that lead to an infant being born with abnormalities. In all cases the mother took Zofran in the baby’s early developmental stages. The complainants also base their charges on various researches that have confirmed that Zofran causes certain types of birth abnormalities. Regardless of these studies GSK does not acknowledge that their drug causes birth deformities.
Despite GSK’s denial these are some of the cited birth abnormalities from litigants:
- Atrial septal defect
- Ventricular septal defect
- Kidney malformations
- Heart murmurs
- Facial dysmorphia
- Webbed toes
- Low set ears
- Bicuspid aortic stenosis
- Supraventricular tachycardia
- Cleft lip/palate
Kentucky Parents Seeking Justice
This website is promoted by various law firms located in different geographical locations. The intention behind ZofranLegal.com is to keep people regularly informed about the Zofran suit. It should be noted that our legal advocates do not have the authority to practice law in the state of Kentucky, however, we are authorized to practice and hold offices in the state of Delaware. Delaware is a state of particular importance because that is where GlaxoSmithKline has its HQ. This also means we can fully stand for your family’s legal rights when a case is filed in Delaware.
There are several ways we can propose for you to file your case. As already mentioned we are authorized to practice law in Delaware, so we may propose you file in Delaware, or we can find another applicable location. Furthermore, a suit can be filed right in Kentucky where you reside using one of our legal network partners.
To learn more about how you can proceed, please call us anytime and we can provide you with more details for your case. Meet our Zofran attorneys here.